Fair enough, I'll give it a go. BTW my background is purely ICT so I have zero medical knowledge.
1. Phase 1 trial with 9 patients dosed. 2. Dose escalation in three cohorts. 3. 1 cohort (n+3) targeting blood cancers and the other 2 cohorts (n=6) targeting solid tumors. 4. Cohort 1 (blood) - 100% disease control in all patients 5. Cohorts 2,3 (solid) - 2/6 achieved disease control and 1 remains stable at day 100. My understanding is that CAR-T is known to be less effective in solid tumors. 6. Other positive safety measures achieved.
I guess if I was one of the 9 patients, even one with Colon/Colorectal (solid) cancers, and possibly zero expectation of living beyond the next few months I'd grab the opportunity to be on this trial with both hands. I suppose you'd be saying "hmmm... not encouraging, I'll think about it a little bit longer, I'm more interested in a 100% cure".
GLTAH and patients
CHM Price at posting:
16.3¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)